Glucagon Blocker and SGLT2 Inhibitor: Winning Combo in T1D?

Adding a glucagon receptor antagonist to SGLT2 inhibitor therapy improved glycemic control, reduced insulin use, and appeared to mitigate risk of diabetic ketoacidosis in patients with T1D.
Medscape Medical News